NCT07396324

Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Conditions

• Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Iparomlimab and Tuvonralimab (QL1706)	5.0mg/kg qw, start from C1D15
DRUG	Paclitaxel	80mg/m\^2 qw
DRUG	Carboplatin	AUC=1.5, D1, 8, 15, every 28 days

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-12-01
• Completion: 2031-12-01
• First posted: 2026-02-09
• Last updated: 2026-02-09

Locations

1 site across 1 country: China